August 2026 in “Dermatology and Therapy” In this study, patient-reported outcomes indicated that greater weight loss with GLP-1RA treatments was associated with increased reports of adverse cosmetic effects such as skin laxity, facial volume loss, and hair shedding, despite improvements in some preexisting inflammatory skin conditions.
April 2026 in “Open MIND” This review article discusses the aesthetic impacts of GLP-1 medications like Ozempic (semaglutide), including "Ozempic Face," skin sagging, and loss of lean mass, and explores potential recovery methods such as biostimulators, HIFU, endolaser, and PRP.
59 citations
,
August 2021 in “Frontiers in Endocrinology” This review discusses the roles and therapeutic effects of GLP-1 receptor agonists on the nervous, cardiovascular, and endocrine systems, but reports no new clinical results, emphasizing the need for further research on their impact on metabolism and tumor relationships in type 2 diabetes patients.
29 citations
,
September 2023 in “Journal of Clinical Medicine” This study found that semaglutide significantly reduced body weight in almost 80% of obese PCOS patients unresponsive to lifestyle changes, often normalizing menstrual cycles with few side effects.
25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.